Canertinib dihydrochloride is an irreversible tyrosine kinase inhibitor of the quinazoline class, historically investigated as a therapeutic candidate for various cancers by targeting EGFR, HER-2, and… Read more
Canertinib dihydrochloride is an irreversible tyrosine kinase inhibitor of the quinazoline class, historically investigated as a therapeutic candidate for various cancers by targeting EGFR, HER-2, and ErbB-4 receptors. Although clinical development for this experimental compound was discontinued, it remains a valuable subject in oncology research, requiring rigorous analytical support. This category provides access to high-quality reference standards, metabolites, and degradation products essential for method development and validation. Researchers utilize these materials, including stable isotope labelled compounds, to conduct precise impurity profiling and quantitative analysis in complex biological matrices. By employing these dedicated analytical standards, laboratories can ensure the accuracy of their investigations into the drug's mechanism of action, metabolic pathways, and structural characterization within a research context.